Charles Schwab Investment Management Inc. Boosts Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Charles Schwab Investment Management Inc. lifted its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 17.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,940,680 shares of the company’s stock after acquiring an additional 288,926 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Recursion Pharmaceuticals were worth $12,789,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of the business. ARK Investment Management LLC grew its position in Recursion Pharmaceuticals by 16.4% in the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock worth $215,949,000 after purchasing an additional 4,626,268 shares during the period. Baillie Gifford & Co. increased its stake in shares of Recursion Pharmaceuticals by 10.5% in the 2nd quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company’s stock worth $199,425,000 after purchasing an additional 2,522,132 shares in the last quarter. Lingotto Investment Management LLP lifted its position in shares of Recursion Pharmaceuticals by 69.0% during the 2nd quarter. Lingotto Investment Management LLP now owns 3,675,077 shares of the company’s stock valued at $27,563,000 after buying an additional 1,500,000 shares in the last quarter. Ghisallo Capital Management LLC purchased a new position in shares of Recursion Pharmaceuticals during the 2nd quarter valued at about $8,250,000. Finally, Perceptive Advisors LLC bought a new position in shares of Recursion Pharmaceuticals during the 2nd quarter valued at approximately $5,769,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on RXRX shares. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Wednesday, November 20th. Jefferies Financial Group reduced their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Finally, Leerink Partners dropped their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $9.25.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 20,000 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $6.16, for a total value of $123,200.00. Following the completion of the sale, the chief executive officer now directly owns 762,656 shares of the company’s stock, valued at $4,697,960.96. The trade was a 2.56 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $6.84, for a total value of $78,297.48. Following the completion of the transaction, the director now directly owns 7,109,875 shares in the company, valued at approximately $48,631,545. This trade represents a 0.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 134,235 shares of company stock worth $895,538 over the last 90 days. Company insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Trading Up 21.5 %

Shares of RXRX opened at $8.01 on Monday. The stock has a market capitalization of $2.30 billion, a PE ratio of -5.24 and a beta of 0.85. The company’s fifty day moving average is $6.61 and its 200 day moving average is $7.32. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $5.60 and a fifty-two week high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The firm had revenue of $26.08 million for the quarter, compared to analysts’ expectations of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm’s quarterly revenue was up 147.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.43) earnings per share. Sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.